Clinical trial
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma…
NCT00006656 · Direct Therapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00006656 |
|---|---|
| Title | Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
| Official title | A Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients With Recurrent Glioblastoma Multiforme |
| Lead sponsor | Direct Therapeutics, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | carmustine in ethanol, conventional surgery |
| Start date | Jun 1, 2000 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: